Fmr LLC Mirum Pharmaceuticals, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Fmr LLC holds 886 shares of MIRM stock, worth $37,212. This represents 0.0% of its overall portfolio holdings.

Number of Shares

886

Previous 20,321 95.64%

Holding current value

$37,212

Previous $510,000 94.12%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$23.57 - $34.85 $458,082 - $677,309	-19,435 Reduced 95.64%	886 $30,000
Q1 2024 May 13, 2024	SELL	$24.92 - $30.02 $11,363 - $13,689	-456 Reduced 2.19%	20,321 $510,000
Q4 2023 Feb 13, 2024	BUY	$27.14 - $34.93 $521,196 - $670,795	19,204 Added 1220.85%	20,777 $613,000
Q3 2023 Nov 13, 2023	SELL	$24.63 - $32.85 $53,422 - $71,251	-2,169 Reduced 57.96%	1,573 $49,000
Q2 2023 Aug 11, 2023	BUY	$23.51 - $30.09 $64,017 - $81,935	2,723 Added 267.22%	3,742 $96,000
Q1 2023 May 11, 2023	BUY	$19.19 - $24.1 $5,603 - $7,037	292 Added 40.17%	1,019 $24,000
Q4 2022 Feb 13, 2023	BUY	$17.59 - $23.83 $914 - $1,239	52 Added 7.7%	727 $14,000
Q3 2022 Nov 10, 2022	BUY	$19.98 - $29.44 $2,137 - $3,150	107 Added 18.84%	675 $14,000
Q2 2022 Aug 12, 2022	SELL	$18.42 - $27.5 $1,510 - $2,255	-82 Reduced 12.62%	568 $11,000
Q1 2022 May 13, 2022	BUY	$15.5 - $23.93 $10,075 - $15,554	650 New	650 $14,000
Q3 2021 Nov 15, 2021	SELL	$13.95 - $20.18 $1.59 Million - $2.31 Million	-114,328 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$15.84 - $20.6 $1.81 Million - $2.36 Million	114,328 New	114,328 $1.98 Million

Others Institutions Holding MIRM

# of Institutions

173

Shares Held

53.5M

Call Options Held

96.1K

Put Options Held

54.8K

View Full List

About Mirum Pharmaceuticals, Inc.

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.54B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

More about MIRM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account